ESC 365 - KAND567, the first selective small molecule CX3CR1 antagonist in clinical development, mediates anti-inflammatory cardioprotective effects in rodent models of atherosclerosis and myocardial infarction

ESC Premium Access

KAND567, the first selective small molecule CX3CR1 antagonist in clinical development, mediates anti-inflammatory cardioprotective effects in rodent models of atherosclerosis and myocardial infarction

Session: Emerging treatments in acute coronary syndromes

Topic: Inflammation

Speaker: Professor I. Spyridopoulos (Newcastle-Upon-Tyne, GB)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Professor Ioakim Spyridopoulos

Newcastle University, Newcastle-Upon-Tyne (United Kingdom of Great Britain & Northern Ireland)

1 presentation

1 follower

3 more presentations in this session

State of the Art - Novel therapies for acute myocardial infarction

Speaker: Professor G. Heusch (Essen, DE)

Inhibition of platelet aggregation after subcutaneous administration of a single-dose of selatogrel, a novel P2Y12 antagonist, in acute myocardial infarction: a randomised open-label phase 2 study

Speaker: Professor P. Sinnaeve (Leuven, BE)

Interleukin-1 blockade with Anakinra in ST-segment elevation acute myocardial infarction: Results from the VCUART3 study

Speaker: Doctor A. Abbate (Charlottesville, US)

Access the full session

Emerging treatments in acute coronary syndromes

Speakers: Professor I. Spyridopoulos, Professor G. Heusch, Professor P. Sinnaeve, Doctor A. Abbate

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources